Stock A009420 HANALL BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-09 pm EDT 		5-day change 1st Jan Change
33,500 KRW -1.90% Intraday chart for Hanall Biopharma Co., Ltd. +6.18% -24.38%
May. 14 Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 03 HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
  • The company's profit outlook over the next few years is a strong asset.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • With an expected P/E ratio at 175.09 and 80.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HANALL BIOPHARMA CO., LTD. Stock Hanall Biopharma Co., Ltd.
-24.38% 1.26B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+47.65% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.42% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.80% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.11% 216B
B-
AMGEN INC. Stock Amgen Inc.
+4.86% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A009420 Stock
  4. Ratings Hanall Biopharma Co., Ltd.